INBX - Inhibrx Biosciences Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$285.00
DETAILS
HIGH:
$325.00
LOW:
$245.00
MEDIAN:
$285.00
CONSENSUS:
$285.00
UPSIDE:
193.51%
About Inhibrx Biosciences Inc. (https://www.inhibrx.com)
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Mark Paul Lappe | Founder, Chief Executive Officer & Chairman | 1967 | $2,892,473 USD |
| David Matly | President | 1986 | $911,655 USD |
| Kelly Devine Deck | Executive Vice President, Chief Financial Officer & Treasurer | 1980 | $766,410 USD |
| Ashraf Amanullah | Executive Vice President & Chief Technical Operations Officer | 1968 | – |
| Bonne Adams | Vice President of Operations | 1977 | – |
| Carlos Bais | EVice President & Chief Scientific Officer | – | – |
| Josep Garcia | Executive Vice President & Chief Clinical Development Officer | – | – |
| Kate Burke | Vice President of Accounting | – | – |
| Leah Pollema | Vice President, General Counsel & Corporate Secretary | – | – |